Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
- PMID: 28356445
- DOI: 10.1161/CIR.0000000000000484
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
Erratum in
-
Correction to: Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.Circulation. 2019 Jul 30;140(5):e181-e184. doi: 10.1161/CIR.0000000000000703. Epub 2019 Jul 29. Circulation. 2019. PMID: 31356128 No abstract available.
Abstract
Background: Kawasaki disease is an acute vasculitis of childhood that leads to coronary artery aneurysms in ≈25% of untreated cases. It has been reported worldwide and is the leading cause of acquired heart disease in children in developed countries.
Methods and results: To revise the previous American Heart Association guidelines, a multidisciplinary writing group of experts was convened to review and appraise available evidence and practice-based opinion, as well as to provide updated recommendations for diagnosis, treatment of the acute illness, and long-term management. Although the cause remains unknown, discussion sections highlight new insights into the epidemiology, genetics, pathogenesis, pathology, natural history, and long-term outcomes. Prompt diagnosis is essential, and an updated algorithm defines supplemental information to be used to assist the diagnosis when classic clinical criteria are incomplete. Although intravenous immune globulin is the mainstay of initial treatment, the role for additional primary therapy in selected patients is discussed. Approximately 10% to 20% of patients do not respond to initial intravenous immune globulin, and recommendations for additional therapies are provided. Careful initial management of evolving coronary artery abnormalities is essential, necessitating an increased frequency of assessments and escalation of thromboprophylaxis. Risk stratification for long-term management is based primarily on maximal coronary artery luminal dimensions, normalized as Z scores, and is calibrated to both past and current involvement. Patients with aneurysms require life-long and uninterrupted cardiology follow-up.
Conclusions: These recommendations provide updated and best evidence-based guidance to healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be individualized to specific patient circumstances.
Keywords: AHA Scientific Statements; Kawasaki syndrome; aneurysm; arteritis; coronary vessels; immunoglobulins, intravenous; thrombosis; vasculitis.
© 2017 American Heart Association, Inc.
Conflict of interest statement
The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.
Similar articles
-
[National consensus on the cardiological treatment and follow-up of Kawasaki disease].An Pediatr (Engl Ed). 2018 Sep;89(3):188.e1-188.e22. doi: 10.1016/j.anpedi.2018.04.003. Epub 2018 May 16. An Pediatr (Engl Ed). 2018. PMID: 29778491 Spanish.
-
State-of-the-art acute phase management of Kawasaki disease after 2017 scientific statement from the American Heart Association.Pediatr Neonatol. 2018 Dec;59(6):543-552. doi: 10.1016/j.pedneo.2018.03.005. Epub 2018 Mar 30. Pediatr Neonatol. 2018. PMID: 29706362 Review.
-
Management of Kawasaki disease in adults.Heart. 2017 Nov;103(22):1760-1769. doi: 10.1136/heartjnl-2017-311774. Epub 2017 Jul 27. Heart. 2017. PMID: 28751537 Review.
-
Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.Pediatrics. 2004 Dec;114(6):1708-33. doi: 10.1542/peds.2004-2182. Pediatrics. 2004. PMID: 15574639
-
Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.Circulation. 2004 Oct 26;110(17):2747-71. doi: 10.1161/01.CIR.0000145143.19711.78. Circulation. 2004. PMID: 15505111
Cited by
-
COVID-19 and cardiac complications: Myocarditis and multisystem inflammatory syndrome in children.World J Cardiol. 2024 May 26;16(5):260-268. doi: 10.4330/wjc.v16.i5.260. World J Cardiol. 2024. PMID: 38817651 Free PMC article. Review.
-
Extensive coronary artery thrombosis in a paediatric patient with Kawasaki disease: a case report.Eur Heart J Case Rep. 2024 May 24;8(5):ytae250. doi: 10.1093/ehjcr/ytae250. eCollection 2024 May. Eur Heart J Case Rep. 2024. PMID: 38817317 Free PMC article.
-
Pharmacogenomics of coronary artery response to intravenous gamma globulin in kawasaki disease.NPJ Genom Med. 2024 May 30;9(1):34. doi: 10.1038/s41525-024-00419-7. NPJ Genom Med. 2024. PMID: 38816462 Free PMC article.
-
[Predictive indicators and risk model construction for coronary artery lesions in Kawasaki disease children over 5 years old].Zhongguo Dang Dai Er Ke Za Zhi. 2024 May 15;26(5):461-468. doi: 10.7499/j.issn.1008-8830.2309103. Zhongguo Dang Dai Er Ke Za Zhi. 2024. PMID: 38802905 Free PMC article. Chinese.
-
Multiresistant Kawasaki Disease in a Young Infant with Giant Aneurysms Growing Fast.J Cardiovasc Dev Dis. 2024 May 14;11(5):149. doi: 10.3390/jcdd11050149. J Cardiovasc Dev Dis. 2024. PMID: 38786971 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous